title: Pazopanib in the treatment of advanced renal cell carcinoma.
abstract: Pazopanib is an orally available multitargeted tyrosine kinase inhibitor (a class of targeted therapies) that inhibits tumor angiogenesis and cell proliferation. The safety and efficacy of pazopanib (noninferior to sunitinib for progression-free survival) in patients with advanced or metastatic renal cell carcinoma (mRCC) have been demonstrated in several clinical trials. However, in addition to therapeutic efficacy, treatment choices should also take into account health-related quality of life (HRQoL) aspects of cancer therapy. Here, we summarize the HRQoL findings related to pazopanib use, based on patient-reported outcome measures; pazopanib has been shown to be superior to sunitinib on several HRQoL domains (including patient preference). A further consideration for treatment choice is how well the findings from clinical trials correlate with evidence from general clinical practice. This review therefore includes descriptions of real-world experience of pazopanib use in the treatment of patients with mRCC, following its approval by medical regulatory authorities in a number of countries. Naturalistic observational studies demonstrate that the efficacy of pazopanib in patients with mRCC is consistent with clinical trial findings. Similarly, consistent results were observed for the safety profile of pazopanib between observational studies and clinical trials, with most treatment-associated adverse events being mild to moderate in severity, and manageable.
authors.affiliation: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 633 N. St. Clair, 19th Floor, Chicago, IL 60611, USA.
authors.forename: David
authors.initials: D
authors.lastname: Cella
authors.affiliation: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Beaumont
keywords: clinical experience; health-related quality of life; metastatic renal cell carcinoma; patient-reported outcomes; pazopanib; tyrosine kinase inhibitors
references.citation: Tumori. 2014 May-Jun;100(3):e87-91
references.pmid: 25076258
references.citation: N Engl J Med. 2013 Aug 22;369(8):722-31
references.pmid: 23964934
references.citation: J Med Econ. 2012;15(6):1139-48
references.pmid: 22808923
references.citation: Eur J Cancer. 2013 Oct;49(15):3169-75
references.pmid: 23810246
references.citation: Pharmacoeconomics. 2011 Nov;29(11):977-88
references.pmid: 21854079
references.citation: J Urol. 2015 Jan;193(1):41-7
references.pmid: 25046616
references.citation: Eur J Cancer. 2012 Feb;48(3):311-23
references.pmid: 21689927
references.citation: J Pain Symptom Manage. 2002 Dec;24(6):547-61
references.pmid: 12551804
references.citation: Clin Ther. 2012 Mar;34(3):511-20
references.pmid: 22341567
references.citation: Cancer. 2016 Jan 15;122(2):287-95
references.pmid: 26457466
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references.pmid: 20100962
references.citation: J Manag Care Spec Pharm. 2014 Jun;20(6):603-10
references.pmid: 24856598
references.citation: Eur J Cancer. 2013 Apr;49(6):1287-96
references.pmid: 23321547
references.citation: N Engl J Med. 2014 May 1;370(18):1769-70
references.pmid: 24785224
references.citation: J Pain Symptom Manage. 2009 Aug;38(2):291-8
references.pmid: 19356897
references.citation: Acta Clin Belg. 2014 Oct;69(5):335-40
references.pmid: 25056491
references.citation: Patient Prefer Adherence. 2014 Apr 22;8:503-11
references.pmid: 24790418
references.citation: Value Health. 2008 Jul-Aug;11(4):669-79
references.pmid: 18194397
references.citation: J Manag Care Spec Pharm. 2015 Jun;21(6):515-22
references.pmid: 26011553
references.citation: Clin Genitourin Cancer. 2015 Jun;13(3):210-7
references.pmid: 25498215
references.citation: J Clin Oncol. 2014 May 10;32(14):1412-8
references.pmid: 24687826
references.citation: Oncology. 2014;87(6):342-50
references.pmid: 25227656
references.citation: Med Oncol. 2014 Sep;31(9):156
references.pmid: 25115744
references.citation: Tumori. 2014 Jul-Aug;100(4):165e-8e
references.pmid: 25296611